Your session is about to expire
← Back to Search
Tranexamic Acid for Skin Pigmentation Disorders
Study Summary
This trial seeks to determine whether tranexamic acid can reduce pigmentation in patients with LPP and EDP.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2008 Phase 3 trial • 196 Patients • NCT00386308Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have experienced migraines accompanied by symptoms like visual disturbances.I have been diagnosed with LPP, EDP, or AD.I am currently on blood thinner medication.I understand what participating in the study involves and its risks.I have used hormonal contraception or hormone therapy in the past month.I stopped using skin color treatment meds, except sunscreen, a month ago.I have an active cancer other than non-melanoma skin cancer.I am 18 years old or older.I have a history of blood clots or stroke.My kidneys do not work well.
- Group 1: Treatment
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What health conditions does Tranexamic acid tablets typically address?
"Tranexamic acid tablets can be applied to treat hyperfibrinolysis, hemophilia, and bleeding."
Is the enrollment process for this experiment still open?
"Affirmative, clinicaltrials.gov verifies that this research is presently recruiting participants. It was initially advertised on March 17th 2020 and recently modified on February 7th 2022. The investigation requires 5 volunteers from a single location."
Has the FDA given its stamp of approval to Tranexamic acid tablets?
"Tranexamic acid tablets have preliminary evidence of safety, so it earned a rating of 2. However, since this is only Phase 2 trial, there isn't any empirical data to support its efficacy."
What is the quota for participants in this medical investigation?
"Indeed, the data listed on clinicaltrials.gov indicates that this examination is actively enrolling individuals. It was originally posted online March 17th 2020 and last edited February 7th 2022. The research needs to acquire 5 patients from only one medical facility."
Could you provide a summary of prior investigations involving Tranexamic acid tablets?
"At the present moment, 61 clinical trials for Tranexamic acid tablets are underway. Of those studies, 26 have progressed to Phase 3. Kaohsiung City, Yanchao District houses the bulk of these investigations; however 185 sites across the globe are also running studies related to this treatment."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger